search
Back to results

Autoimmune Cytopenia: Genetics and Pathophysiological Mechanism in Pediatric Evans Syndrome (ACTION)

Primary Purpose

Evans Syndrome

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
blood sample
Sponsored by
University Hospital, Bordeaux
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Evans Syndrome focused on measuring pediatric Evans Syndrome, genetic causes, immunophenotyping immunologic explorations

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient registered in the French national prospective OBS'CEREVANCE cohort
  • Diagnosis of pediatric Evans syndrome (PTI+AHAI)
  • Age strictly under 18 years at the initial onset
  • Child residing in metropolitan France and affiliated to a french health insurance system
  • Free, informed, written and signed consent

Exclusion Criteria:

  • Evans syndrome secondary to chemotherapy, bone marrow transplantation or organ transplantation.
  • Refusal to participate from parents/patients

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Other

    Arm Label

    pediatric Evans Syndrome

    Arm Description

    Collection of biological samples of children with pSE included in the the OBS'CEREVANCE cohort and their parents, for genetic and functional immunological analyzes.

    Outcomes

    Primary Outcome Measures

    Number of patients for whom a causal mutation has been identified (known or new)
    The number of biological samples collected for PSE children included in the OBS'CEREVANCE cohort and their relatives will be recorded

    Secondary Outcome Measures

    Immunopathological clinical manifestations
    Abnormalities of lymphocyte immunophenotyping
    The correlation between causal mutations identified with the clinical and immunological phenotype
    Physiopathological and potentially therapeutic classification of pES-T

    Full Information

    First Posted
    April 9, 2019
    Last Updated
    April 9, 2019
    Sponsor
    University Hospital, Bordeaux
    Collaborators
    Institut des maladies génétiques, Paris
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03912129
    Brief Title
    Autoimmune Cytopenia: Genetics and Pathophysiological Mechanism in Pediatric Evans Syndrome
    Acronym
    ACTION
    Official Title
    Autoimmune Cytopenia: Genetics and Pathophysiological Mechanism in Pediatric Evans Syndrome
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2019
    Overall Recruitment Status
    Unknown status
    Study Start Date
    May 6, 2019 (Anticipated)
    Primary Completion Date
    May 6, 2022 (Anticipated)
    Study Completion Date
    May 6, 2022 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University Hospital, Bordeaux
    Collaborators
    Institut des maladies génétiques, Paris

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Characterization of the genetic causes, and of the immunopathological clinical and biological manifestations in children with pediatric Evans syndrome included in a prospective national observational cohort of rare diseases.
    Detailed Description
    Pediatric Evans syndrome (pES) is a rare and severe disease combining immunologic thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia (AIHA). French patients from the 30 hematologic pediatric centers are from 2004 included in a prospective national OBS'CEREVANCE cohort. A first pilot study revealed a monogenic cause in 7/18 patients (40%) with mutations in the CTLA-4, LRBA, STAT3 GOF, and KRAS. TNGS or exome studies were performed between 2015 and 2018 inn 80 patients with pSE from the OBS'CEREVANCE cohort. This approach, combined with by immunophenotyping lymphocyte, identified a genetic cause of the disease in 26 patients (32%) (TNFRSF6, CTLA4, LRBA, STAT3 GOF, PIK3CD, RAG1, KRAS) and potential causal mutations in 18 other patients (22%), bringing the proportion of potential single gene cause to 76%. The central hypothesis of this study is that most, if not all, cases of pSE are related to a monogenic or digenic cause, possibly with the intervention of genetic modifiers such as somatic mutations.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Evans Syndrome
    Keywords
    pediatric Evans Syndrome, genetic causes, immunophenotyping immunologic explorations

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    200 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    pediatric Evans Syndrome
    Arm Type
    Other
    Arm Description
    Collection of biological samples of children with pSE included in the the OBS'CEREVANCE cohort and their parents, for genetic and functional immunological analyzes.
    Intervention Type
    Genetic
    Intervention Name(s)
    blood sample
    Intervention Description
    A first systematic approach by Targeted-Next Generation Sequencing will be used on the entire cohort of patients with pSE. This step will be performed on a sequencing chip specifically developed to detect anomalies in known genes involved in autoimmunity. In patients for whom no mutations are identified, a whole exome sequencing (WES) approach will be applied to patients and their parents to seek to identify mutations in new genes that may be related to pSE. In patients for whom this WES approach is unsuccessful, the search for somatic lymphocyte mutations, or copy number variants will be performed before considering a complete genome sequencing . If several candidate genes are identified, the clinical data provided by the CEREVANCE and the phenotypic analyses carried out prior to genetic analyses by the CEDI laboratory will guide the choices to prioritize the study of the identified variants.
    Primary Outcome Measure Information:
    Title
    Number of patients for whom a causal mutation has been identified (known or new)
    Time Frame
    after the genetic analyzes carried out on all the participants included, may 2022
    Title
    The number of biological samples collected for PSE children included in the OBS'CEREVANCE cohort and their relatives will be recorded
    Time Frame
    every 3 months, between may 2019 and may 2022
    Secondary Outcome Measure Information:
    Title
    Immunopathological clinical manifestations
    Time Frame
    after the genetic analyzes carried out on all the participants included, may 2022
    Title
    Abnormalities of lymphocyte immunophenotyping
    Time Frame
    after the genetic analyzes carried out on all the participants included, may 2022
    Title
    The correlation between causal mutations identified with the clinical and immunological phenotype
    Time Frame
    after the genetic analyzes carried out on all the participants included, may 2022
    Title
    Physiopathological and potentially therapeutic classification of pES-T
    Time Frame
    after the genetic analyzes carried out on all the participants included, may 2022

    10. Eligibility

    Sex
    All
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patient registered in the French national prospective OBS'CEREVANCE cohort Diagnosis of pediatric Evans syndrome (PTI+AHAI) Age strictly under 18 years at the initial onset Child residing in metropolitan France and affiliated to a french health insurance system Free, informed, written and signed consent Exclusion Criteria: Evans syndrome secondary to chemotherapy, bone marrow transplantation or organ transplantation. Refusal to participate from parents/patients
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Nathalie Aladjidi, M.D
    Phone
    05 57 82 02 79
    Email
    nathalie.aladjidi@chu-bordeaux.fr
    First Name & Middle Initial & Last Name or Official Title & Degree
    Aurore CAPELLI, PhD
    Phone
    05 57 82 08 77
    Email
    aurore.capelli@chu-bordeaux.fr

    12. IPD Sharing Statement

    Learn more about this trial

    Autoimmune Cytopenia: Genetics and Pathophysiological Mechanism in Pediatric Evans Syndrome

    We'll reach out to this number within 24 hrs